EUVIMEDEUVIMED entdecken
LeitlinieOpen Access · CC BY-NC-ND 4.0

Start, switch and stop (triple‐S) criteria for enzyme replacement therapy of late‐onset Pompe disease: European Pompe Consortium recommendation update 2024

Benedikt Schoser iD, Nadine A M E van der Beek iD, Alexander Broomfield, Esther Brusse, Jordi Diaz-Manera iD, Andreas Hahn, Thomas Hundsberger iD, Cornelia Kornblum iD, Michelle Kruijshaar, Pascal Laforet iD, Eugen Mengel, Tiziana Mongini und 11 weitere

European Journal of Neurology · 2024-09 · 31 (9)

DOI: 10.1111/ene.16383 ↗

Kurz gefasst

Leitlinie in der Zeitschrift European Journal of Neurology, online erschienen am 14.06.2024. Verfasst von Benedikt Schoser und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Friedrich-Baur-Institute, LMU Clinics Munich, Munich, Germany. Hauptthemen laut MEDLINE: Glycogen Storage Disease Type II, Enzyme Replacement Therapy. Die Arbeit wurde bisher 40-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and purpose Two novel enzyme replacement therapies (ERTs), studied in phase 3 trials in late‐onset Pompe patients, reached marketing authorization by the European Medicines Agency in 2022 and 2023. The European Pompe Consortium (EPOC) updates and extends the scope of the 2017 recommendations for starting, switching and stopping ERT.

Methods

The European Pompe Consortium consists of 25 neuromuscular and metabolic experts from eight European countries. This update was performed after an in‐person meeting, three rounds of discussion and voting to provide a consensus recommendation.

Results

The patient should be symptomatic, that is, should have skeletal muscle weakness or respiratory muscle involvement. Muscle magnetic resonance imaging findings showing substantial fat replacement can support the decision to start in a patient‐by‐patient scenario. Limited evidence supports switching ERT if there is no indication that skeletal muscle and/or respiratory function have stabilized or improved during standard ERT of 12 months or after severe infusion‐associated reactions. Switching of ERT should be discussed on a patient‐by‐patient shared‐decision basis. If there are severe, unmanageable infusion‐associated reactions and no stabilization in skeletal muscle function during the first 2 years after starting or switching treatment, stopping ERT should be considered. After stopping ERT for inefficacy, restarting ERT can be considered. Six‐monthly European Pompe Consortium muscle function assessments are recommended.

Conclusions

The triple‐S criteria on ERT start, switch and stop include muscle magnetic resonance imaging as a supportive finding and the potential option of home infusion therapy. Six‐monthly long‐term monitoring of muscle function is highly recommended to cover insights into the patient's trajectory under ERT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glycogen Storage Disease Type IIEnzyme Replacement TherapyHumansEurope

Stichwörter der Autor:innen

EPOCPompe diseaseenzyme replacement therapylate‐onsettherapy switch

Autor:innen und Institutionen

  • Department of Neurology, Friedrich-Baur-Institute, LMU Clinics Munich, Munich, Germany.
  • Department of Neurology, Center for Lysosomal and Metabolic Diseases, Erasmus MC, University Medical Center, Rotterdam, The Netherlands.
  • Metabolic Department, Great Ormond Street Hospital, London, UK.
  • John Walton Muscular Dystrophy Research Center, Newcastle University Translational and Clinical Research Institute, Newcastle Upon Tyne, UK.
  • Department of Child Neurology, Justus-Liebig-University Giessen, Giessen, Germany.
  • Department of Neurology, Cantonal Hospital St Gallen, St Gallen, Switzerland.

ORCID-Profile: Benedikt Schoser, Nadine A M E van der Beek, Jordi Diaz-Manera, Thomas Hundsberger, Cornelia Kornblum, Pascal Laforet, W W M Pim Pijnappel, Thomas Scherer, John Vissing, Pieter A van Doorn, Stephan Wenninger, Ans T van der Ploeg

Zitieren

APA

Schoser, B., van der Beek, N. A. M. E., Broomfield, A., Brusse, E., Diaz-Manera, J., Hahn, A., Hundsberger, T., Kornblum, C., Kruijshaar, M., Laforet, P., Mengel, E., Mongini, T., Orlikowski, D., Parenti, G., Pijnappel, W. W. M. P., Roberts, M., Scherer, T., Toscano, A., Vissing, J., …, & van der Ploeg, A. T. (2024). Start, switch and stop (triple‐S) criteria for enzyme replacement therapy of late‐onset Pompe disease: European Pompe Consortium recommendation update 2024. European Journal of Neurology, 31(9). https://doi.org/10.1111/ene.16383

Vancouver

Schoser B, van der Beek NAME, Broomfield A, Brusse E, Diaz-Manera J, Hahn A, et al. Start, switch and stop (triple‐S) criteria for enzyme replacement therapy of late‐onset Pompe disease: European Pompe Consortium recommendation update 2024. European Journal of Neurology. 2024;31(9). doi:10.1111/ene.16383

BibTeX
@article{Schoser2024,
  author = {Schoser, Benedikt and van der Beek, Nadine A M E and Broomfield, Alexander and Brusse, Esther and Diaz-Manera, Jordi and Hahn, Andreas and Hundsberger, Thomas and Kornblum, Cornelia and Kruijshaar, Michelle and Laforet, Pascal and Mengel, Eugen and Mongini, Tiziana and Orlikowski, David and Parenti, Giancarlo and Pijnappel, W W M Pim and Roberts, Mark and Scherer, Thomas and Toscano, Antonio and Vissing, John and van den Hout, Johanna M P and van Doorn, Pieter A and Wenninger, Stephan and van der Ploeg, Ans T},
  title = {Start, switch and stop (triple‐S) criteria for enzyme replacement therapy of late‐onset Pompe disease: European Pompe Consortium recommendation update 2024},
  journal = {European Journal of Neurology},
  year = {2024},
  volume = {31},
  number = {9},
  doi = {10.1111/ene.16383}
}
Kostenlos starten →